Hosted by Evercore healthcare equity research analysts, Skye executives join with notable obesity physicians to discuss the CB1 pathway, nimacimab’s peripheral CB1 blockade, and the broader non-incretin toolkit supporting obesity care beyond the limits of the GLP-1 era.